The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

What is the potential impact of CURATE.AI on clinical practice in myeloma?

May 19, 2020

During the American Association for Cancer Research (AACR) virtual meeting in April 2020, Agata Blasiak, N.1 Institute for Health, NUS, Singapore, SG, presented a poster session about the application of CURATE.AI in multiple myeloma (MM). CURATE.AI is a phenotypic precision medicine (PPM) platform designed to optimize dosing that has been clinically validated and is now being investigated in MM.

Following the AACR meeting, the Multiple Myeloma Hub was pleased to speak to Chng Wee Joo, National University Cancer Institute, Singapore, SG, and Agata Blasiak, about how CURATE.AI may be used to optimize dosing within MM regimens, for individual patients. It was noted that the engineering team are working closely with treating physicians to optimize the platform with the aim of generating effective responses to therapy with minimal toxicity.

What is the potential impact of CURATE.AI on clinical practice in myeloma?